Sonnet BioTherapeutics Holdings, Inc. (SONN)
$1.26-59.35%Close
SELLCRISIS · day 9
Key stats
- Market cap
- $8M
- Beta
- 1.47
- P/E (TTM)
- -0.84
- 1W
- -74.02%
- 1M
- -74.90%
- vs SPY 1W
- -73.04%
- vs SPY 1M
- -76.77%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 22
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-146.7%
REV YoY-
ROE-244.4%
EPS YoY-
ROA-63.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.84
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.48
P/FCF-
EV/EBITDA0.47
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.43
ALTMAN Z-
CURR RATIO3.50
ND/EBITDA-
BETA1.47
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on SONN?
- LOPJLB’s latest quantitative signal on Sonnet BioTherapeutics Holdings, Inc. (SONN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SONN in?
- Sonnet BioTherapeutics Holdings, Inc. (SONN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Sonnet BioTherapeutics Holdings, Inc. (SONN) do?
- Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This …